Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation

Hepatology

Volumn 40, Issue 1, 2004, Pages 243-251

  Otsuka, Motoyuki ^a   Kato, Naoya ^a   Shao, Run Xuan ^a   Hoshida, Yujin ^a   Ijichi, Hideaki ^a   Koike, Yukihiro ^a,b   Taniguchi, Hiroyoshi ^a   Moriyama, Masaru ^a   Shiratori, Yasushi ^a,c   Kawabe, Takao ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b The Mutualaid Association of Public School Teachers)   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; DECARBOXYPROTHROMBIN; FARNOQUINONE; MK 4; PLASMA PROTEIN; RETINOID; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; CDC25A PROTEIN; PROTEIN TYROSINE PHOSPHATASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PORTAL VEIN; PRIORITY JOURNAL; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION; ANIMAL; CANCER TRANSPLANTATION; CELL DIVISION; CELL STRAIN 3T3; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; LIVER TUMOR; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CDC25 PHOSPHATASE; CELL DIVISION; CELL LINE, TUMOR; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME ACTIVATION; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NIH 3T3 CELLS; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; VITAMIN K 2;

EID: 3042697863     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20260     Document Type: Article

References (48)

1. Wong F, Choi TK. Primary liver cancer. Asian experience. In: Blumgart LH, editor. Surgery of Liver and Biliary Tract. London: Churchill-Livingstone, 1998:1135-1151.
2. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. HEPATOLOGY 2002;36:S74-S83.
3. Johnson PJ. Hepatocellular carcinoma: is current therapy really altering outcome? Gut 2002;51:459-462.
4. Shiina S, Teratani T, Obi S, Hamamura K, Koike Y, Omata M. Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 2002;62:64-68.
5. Pompili M, Rapaccini GL, Covino M, Pignataro G, Caturelli E, Siena DA, et al. Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. Cancer 2001;92:126-135.
6. Albacete RA, Matthews MJ, Saini N. Portal vein thromboses in malignant hepatoma. Ann Intern Med 1967;67:337-348.
7. Adachi E, Maeda T, Kajiyama K, Kinukawa N, Matsumata T, Sugimachi K, et al. Factors correlated with portal venous invasion by hepatocellular carcinoma: univariate and multivariate analyses of 232 resected cases without preoperative treatments. Cancer 1996;77:2022-2031.
8. Hsu HC, Wu TT, Wu MZ, Sheu JC, Lee CS, Chen DS. Tumor invasiveness and prognosis in resected hepatocellular carcinoma. Clinical and pathogenetic implications. Cancer 1998;61:2095-2099.
9. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001;91:561-569.
10. Tagawa M, Omata M, Ohto M. Nucleotide sequence of prothrombin gene in abnormal prothrombin-producing hepatocellular carcinoma cell lines. Cancer 1992;69:643-647.
11. Miyakawa T, Kajiwara Y, Shirahata A, Okamoto K, Itoh H, Ohsato K. Vitamin K contents in liver tissue of hepatocellular carcinoma patients. Jpn J Cancer Res 2000;91:68-74.
12. Shearer MJ. Vitamin K. Lancet 1995;345:229-234.
13. Sakon M, Monden M, Gotoh M, Kobayashi K, Kanai T, Umeshita K, et al. The effects of vitamin K on the generation of des-gamma-carboxy prothrombin (PIVKA-II) in patients with hepatocellular carcinoma. Am J Gastroenterol 1991;86:339-345.
14. Koike Y, Shiratori Y, Shiina S, Teratani T, Obi S, Sato S, et al. Randomized prospective study of prevention from tumor invasion into portal vein in 120 patients with hepatocellular carcinoma by vitamin K-II administration [Abstract]. Gastroenterology 2002;122:643a.
15. Olson RE. Osteoporosis and vitamin K intake. Am J Clin Nutr 2000;71:1031-102.
16. Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. Bone Miner Res 2000;15:515-521.
17. Song Z, Powell WC, Kasahara N, van Bokhoven A, Miller GJ, Roy-Burman P. The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells. Cancer Res 2000;60:6730-6736.
18. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001;29:365-371.
19. Schreiber E, Matthias P, Muller MM, Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 1989;17:6419.
20. Constantinescu A, Gordon AS, Diamond I. cAMP-dependent protein kinase types I and II differentially regulate cAMP response element-mediated gene expression: implications for neuronal responses to ethanol. J Biol Chem 2002;277:18810-18816.
21. Chen S, Gardner DG. Suppresion of WEE1 and stimulation of CDC25A correlates with endothelin-dependent proliferation of rat aortic smooth muscle cells. J Biol Chem 2004;279:13745-13763.
22. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984;310:1427-1431.
23. Long WP, Chen X, Perdew GH. Protein kinase C modulates aryl hydrocarbon receptor nuclear translocator protein-mediated transactivation potential in a dimer context. J Biol Chem 1999;274:12391-12400.
24. Garcia MA, Campillos M, Marina A, Valdivieso F, Vazquez J. Transcription factor AP-2 activity is modulated by protein kinase A-mediated phosphorylation. FEBS Lett 1999;444:27-31.
25. Nichols M, Weih F, Schmid W, DeVack C, Kowenz-Leutz E, Luckow B, et al. Phosphorylation of CREB affects its binding to high and low affinity sites: implications for cAMP induced gene transcription. EMBO J 1992;11:3337-3346.
26. Kar S, Wang M, Wilcox CS, Carr BI. Antitumor and anticarcinogenic actions of Cpd 5: a new class of protein phosphatase inhibitor. Carcinogenesis 2003;24:411-416.
27. Zhao H, Watkins JL, Piwnica-Worms H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci U S A 2002;99:14795-14800.
28. Xiao Z, Chen Z, Gunasekera AH, Sowin TJ, Rosenberg SH, Fesik S, et al. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem 2003;278:21767-21773.
29. Wang Z, Wang M, Finn F, Carr BI. The growth inhibitory effects of vitamins K and their actions on gene expression. HEPATOLOGY 1995;22:876-882.
30. Nishikawa Y, Carr BI, Wang M, Kar S, Finn F, Dowd P, et al. Growth inhibition of hepatoma cells induced by vitamin K and its analogs. J Biol Chem 1995;270:28304-28310.
31. Akedo Y, Hosoi T, Inoue S, Ikegami A, Mizuno Y, Kaneki M, et al. Vitamin K2 modulates proliferation and function of osteoblastic cells in vitro. Biochem Biophys Res Commun 1992;187:814-820.
32. Miyazawa K, Yaguchi M, Funato K, Gotoh A, Kawanishi Y, Nishizawa Y, et al. Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells. Leukemia 2001;15:1111-1117.
33. Tabb MM, Sun A, Zhou C, Grun F, Errandi J, Romero K, et al. Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem 2003;278:43919-43927.
34. Zeng YX, Somasundaram K, el-Deiry WS. AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat Genet 1997;15:78-82.
35. Luo X, Sawadogo M. Antiproliferative properties of the USF family of helix-loop-helix transcription factors. Proc Natl Acad Sci U S A 1996;93:1308-1313.
36. Dumaz N, Light Y, Marais R. Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms. Mol Cell Biol 2002;22:3717-3728.
37. McKenzie FR, Pouyssegur J. cAMP-mediated growth inhibition in fibroblasts is not mediated via mitogen-activated protein (MAP) kinase (ERK) inhibition. cAMP-dependent protein kinase induces a temporal shift in growth factor-stimulated MAP kinases. J Biol Chem 1996;271:13476-13483.
38. Duckworth BC, Weaver JS, Ruderman JV. G2 arrest in Xenopus oocytes depends on phosphorylation of cdc25 by protein kinase A. Proc Natl Acad Sci U S A 2002;99:16794-16799.
39. Lang P, Gesbert F, Delespine-Carmagnat M, Stancou R, Pouchelet M, Bertoglio J. Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. EMBO J 1996;15:510-519.
40. Maat B, Hilgard P. Anticoagulants and experimental metastases-evaluation of antimetastatic effects in different model systems. J Cancer Res Clin Oncol 1981;101:275-283.
41. Kempen I, Papapostolou D, Thierry N, Pochet L, Counerotte S, Masereel B, et al. 3-Bromophenyl 6-acetoxymethyl-2-oxo-2H-1-benzopyran-3-carboxylate inhibits cancer cell invasion in vitro and tumour growth in vivo. Br J Cancer 2003;88:1111-1118.
42. Dulin NO, Niu J, Browning DD, Ye RD, Voyno-Yasenetskaya T. Cyclic AMP-independent activation of protein kinase A by vasoactive peptides. J Biol Chem 2001;276:20827-20830.
43. Ferraris JD, Persaud P, Williams CK, Chen Y, Burg MB. cAMP-independent role of PKA in tonicity-induced transactivation of tonicity-responsive enhancer/osmotic response element-binding protein. Proc Natl Acad Sci U S A. 2002;99:16800-16805.
44. Tsang CK, Kamei Y. Novel effect of vitamin K(1) (phylloquinone) and vitamin K(2) (menaquinone) on promoting nerve growth factor-mediated neurite outgrowth from PC12D cells. Neurosci Lett 2002;323:9-12.
45. Sugimoto T, Yamakado M, Matsushita K, Iwamoto T, Tagawa H. Pharmacodynamics of menatetrenone and effects on bone metabolism in continuous ambulatory peritoneal dialysis patients. J Int Med Res 2002;30:566-575.
46. Konishi T, Baba S, Sone H. Whole-body autoradiographic study of vitamin K distribution in rat. Chem Pharm Bull 1973;21:220-224.
47. Li ZQ, He FY, Stehle CJ, Wang Z, Kar S, Finn FM, Carr BI. Vitamin K uptake in hepatocytes and hepatoma cells. Life Sci 2002;70:2085-2100.
48. Carr BI, Wang Z, Kar S. K vitamins, PTP antagonism, and cell growth arrest. J Cell Physiol 2002;193:263-274.